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For many decades, urate-lowering therapy consisted of 
allopurinol, a xanthine-oxidase inhibitor and uricosurics, 
such as probenecid, sulﬁ  npyrazone and benzbromarone. 
Febuxostat, another xanthine inhibitor, was approved in 
2009 in the US, Canada, Japan and the European Union 
for the treatment of hyperuricemia in gout patients. Gout 
is associated with high medical comorbidity and deﬁ  cits 
in health-related quality of life. In a previous issue of 
Arthritis Research and Th  erapy, Becker and colleagues 
[1] describe a non-inferiority randomized controlled trial 
(RCT) of febuxostat compared to allopurinol in 2,269 
patients with gout. Several ﬁ   ndings of this important 
study merit discussion.
Th   e cornerstone of gout treatment is achievement of a 
target serum urate <6  mg/dl. Th  is therapeutic goal is 
based on the solubility of urate at 37°C (6.8 mg/dl), levels 
below which have been associated with lower risk of gout 
ﬂ  ares and tophi [2-4]. A target serum urate was achieved 
in signiﬁ  cantly more patients in the febuxostat 80  mg 
group (67%) compared to the 40 mg group (45%) and the 
allopurinol group (42%; 300 mg daily or 200 mg daily in 
moderate renal impairment); the 40 mg febuxostat dose 
was not inferior to allopurinol [5]. First, the superiority of 
febuxostat 80 mg/day to allopurinol 300 mg/day in 
achiev  ing serum urate <6 mg/dl in this study conﬁ  rms 
similar ﬁ  ndings from previous RCTs of febuxostat using 
this or higher doses of febuxostat (120 and 240 mg daily) 
[5-7]. Th   is study provides evidence for non-inferiority of 
a febuxostat 40 mg dose compared to allopurinol in 
achieving a target serum urate <6 mg/dl. One important 
fact to bear in mind, however, is that the allopurinol dose 
should be optimally titrated between 100 and 800 mg/day 
in clinical settings (or even higher doses in some cases 
according to experts) to achieve a target serum urate 
<6 mg/dl, and all febuxostat studies to date have used 200 
or 300 mg allopurinol as the comparator. Th  erefore,  these 
studies do not answer an important question: is 
febuxostat superior to a titrated dose of allopurinol in the 
treatment of hyperuricemia in patients with gout? We 
know now that allopurinol doses of ≤300 mg/day fail to 
adequately treat hyperuricemia in 50% of gout patients 
[8]. It should be noted that, in practice, many physicians 
do not adequately titrate allopurinol and fail to follow 
serum urate to achieve the target level [9-10]. Th  us,  there 
is limited ‘real world logic’ in such a study design strategy.
Second, this study provides safety data as one of its 
important secondary outcomes. Th  is ﬁ   nding has high 
relevance since cardiovascular adverse outcomes were an 
early safety signal in the ﬁ  rst large febuxostat RCT, with 
four deaths in the two febuxostat groups and no deaths in 
the allopurinol group [5]. In the current study, febuxostat 
was well-tolerated and not associated with signiﬁ  cantly 
more cardiovascular adverse events compared to allo-
purinol [1]. Cardiovascular adverse events as deﬁ  ned by 
the Adjudicated Antiplatelet Trialists Collaboration 
(APTC; cardiovascular death, nonfatal myocardial infarc-
tion, and nonfatal stroke) occurred in 0% of patients in 
the febuxostat 40 mg group, 0.4% in the febuxostat 80 mg 
group and 0.4% in the allopurinol group, without a 
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In a previous issue of the journal, Becker and colleagues 
present effi   cacy and safety data from a large study 
comparing febuxostat to allopurinol. The study showed 
non-inferiority of febuxostat 40 mg/day in lowering 
serum urate compared to allopurinol 200 to 300 mg/
day. More importantly, the study showed a similar 
frequency of important cardiovascular adverse events 
(cardiovascular death, nonfatal myocardial infarction 
and nonfatal stroke) for febuxostat 40 mg/day 
(0%), febuxostat 80 mg/day (0.4%) and allopurinol 
groups (0.4%). Other cardiac adverse event rates 
(unstable angina, coronary revascularization, cerebral 
revascularization, transient ischemic attack, venous and 
peripheral arterial vascular thrombotic event, congestive 
heart failure, and arrhythmia) were also similar for 
febuxostat 40 mg/day (1.3%), febuxostat 80 mg/day 
(1.2%) and allopurinol groups (0.9%). A meta-analysis of 
safety data from published studies is presented.
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(unstable angina, coronary revascularization, cerebral 
revascularization, transient ischemic attack, venous and 
peripheral arterial vascular thrombotic event, congestive 
heart failure, and arrhythmia) occurred in 1.3%, 1.2% and 
0.9%, respectively. A review of RCTs of febuxostat 
showed that cardiovascular adverse events were reported 
in 1.3 to 2% of febuxostat-treated patients versus 0.4 to 
0.9% of allopurinol-treated patients, and death occurred 
in 0 to 1% of febuxostat-treated patients versus 0 to 0.4% 
of allopurinol-treated patients (Table 1). Th  ese diﬀ  er-
ences were not statistically signiﬁ  cantly diﬀ  erent in each 
study.
A meta-analysis of data provided in Table 1 was 
performed by combining the 40 mg, 80 mg and 120 mg 
daily doses of febuxostat into a single category. Th  e 
relative risk of cardiovascular adverse events (APTC and 
non-APTC combined) in febuxostat compared to allo-
purinol (200/300 mg) was 1.7 (95% conﬁ  dence interval 
(CI) 0.4, 7.0) and compared to placebo was 2.5 (95% CI 
0.3, 19.4), with neither statistically signiﬁ  cant (since the 
95% CI included one). Th   e relative risks for mortality and 
serious adverse events was 1.0 (95% CI 0.1, 12.8) and 0.9 
(95% CI 0.5, 1.7), respectively, for febuxostat compared to 
allopurinol; for febuxostat compared to placebo, these 
were not estimable (no deaths occurred in either group) 
and 2.5 (95% CI 0.7, 9.0), respectively. Although none of 
these comparisons were statistically signiﬁ  cant, there was 
a non-signiﬁ   cant trend towards more serious adverse 
events in febuxostat compared to placebo, but no 
diﬀ  erence when compared to allopurinol. A limitation of 
this meta-analysis is the presence of signiﬁ  cant hetero-
geneity (as assessed by I2 statistic of >50%): cardiovascular 
adverse events (I2, 48%), mortality (I2, 58%) and serious 
adverse events (I2, 41%). A 5-year open-label study [3] of 
patients taking febuxostat 40 to 120 mg found 18% (21 of 
116) suﬀ  ered serious adverse events and 5% (6 of 116) 
suﬀ  ered cardiovascular adverse events. Another limita-
tion is that outcomes were assessed at diﬀ  erent  time 
points for adverse events due to varying lengths of RCTs.
Th  e data regarding safety presented in this study are 
important. Associations of hyperuricemia with cardio-
vascular risk are well known [11]. In addition, recent 
evidence also suggests that gout is an independent risk 
factor for overall cardiovascular mortality [12] and for 
myocardial infarction, after adjusting for hyperuricemia-
associated risk [13]. So, why would febuxostat, a medi-
cation that lowers serum urate (a cardiac risk factor), 
Table 1. Serious adverse events, cardiovascular adverse events and mortality in randomized controlled trials of 
febuxostat 
   Febuxostat  Febuxostat  Febuxostat  Allopurinol
Study  Duration  40 mg/day  80 mg/day  120 mg/day  200/300 mg/day  Placebo
Cardiovascular adverse events           
Schumacher et al. [7]  1 month  -  5/267 (2%)a  5/269 (2%)  1/268 (0.4%)  1/134 (0.7%)
Current study [1]  6 months  APTC: 0/757 (0%)  APTC: 3/756 (0.4%)  -  APTC: 3/756 (0.4%)  -
    Non-APTC: 10/757 (1.3%)  Non-APTC: 9/756 (1.2%)    Non-APTC: 7/756 (0.9%) 
        
          
Death          
Schumacher et al. [7]  1 month  -  0/267 (0%)a  0/269 (0%)  0/268 (0%)  0/134 (0%)
Becker et al. [6]  1 month  0/37 (0%)  0/40 (0%)  0/38 (0%)  -  0/38 (0%)
Current study [1]  6 months  1/757 (0.1%)  1/756 (0.1%)  -  3/756 (0.4%)  -
Becker et al. [5]  1 year  -  2/256 (1%)  2/251 (1%)  0/253 (0%)  -
          
Serious adverse events as defi  ned in each studyb          
Schumacher et al. [7]  1 month  -  11/267 (4%)a  9/269 (3%)  7/268 (3%)  2/134 (1%)
Becker et al. [6]  1 month  0/37 (0%)  1/40 (2.5%)  2/38 (5.5%)  -  0/38 (0%)
Current study [1]  6 months  19/757 (2.5%)  28/756 (3.7%)  -  31/756 (4.1%)  -
Becker et al. [5]  1 year  -  11/256 (4.3%)  21/251 (8.4%)  19/253 (7.5%)  -
aOne out of 134 (1%) had cardiovascular adverse events, 5 out of 134 (4%) had serious adverse events and none of the patients died in the 240 mg febuxostat 
group in the study by Schumacher and colleagues [7]. Adjudicated Antiplatelet Trialists Collaboration (APTC) events were defi  ned as one or more of the following: 
cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. Non-APTC cardiovascular events included unstable angina, coronary revascularization, 
cerebral revascularization, transient ischemic attack, venous and peripheral arterial vascular thrombotic event, congestive heart failure, and arrhythmia. aSerious 
adverse events were defi  ned as follows in each study: no defi  nitions were provided in the Schumacher and colleagues [7], Becker and colleagues [6] or the current 
study [1]; Becker and colleagues [5] defi  ned a serious adverse event as ‘…an event that was life-threatening or that resulted in death, hospitalization or prolongation 
of hospitalization, persistent disability or incapacity, or a congenital anomaly or birth defect.’
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important issues that need to be addressed before we 
seek answers to this question: ﬁ  rst, is the cardiovascular 
risk increased with febuxostat treatment compared to 
allopurinol or other urate-lowering agents, as was 
suspected with the initial RCT [5]? And second, is urate-
lowering below a certain level (<4 or <3 mg/dl or some 
threshold) undesirable since lowering urate too much or 
too rapidly may create oxidative stress that could 
predispose to cardiovascular outcomes? We need well-
designed large database or registry post-marketing sur-
veillance studies with validated, adjudicated cardio-
vascular outcomes to answer these important questions. 
While randomized studies of febuxostat with safety as 
the primary outcome would also be helpful, clinical trials 
often are of insuﬃ   cient size, duration of follow-up, or 
have patients with insuﬃ   cient generalizability to address 
such questions. It is possible that ‘J’ or ‘U’ shaped curves 
similar to ones observed for blood pressure and stroke 
risk [14] and diastolic blood pressure and cardiovascular 
outcomes in patients with coronary artery disease [15] 
may apply to serum urate and cardiovascular risk as well. 
In this exciting era of availability of new gout treatments 
and high-quality epidemiological and outcomes studies 
in gout, several existing questions will (need to) be 
answered and several new ones will likely emerge.
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